Hirotsu Bio Science Inc. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Takaaki Hirotsu) has signed a memorandum of understanding with the Global Health Equity Fund (GHEF), an impact fund that aims to support and create impacts that lead to solutions to global health issues, to expand N-NOSE overseas to countries with underdeveloped healthcare systems.
The Global Health Equity Fund (GHEF), established through a partnership between the WHO Foundation and venture capital firm OurCrowd, is an impact investment fund that aims to promote the permeation of innovative medical treatments that utilize groundbreaking technologies to improve the health conditions of people living in vulnerable low- and middle-income countries and regions, and to bring about healthier lives for humanity on a global scale while pursuing profitability.
This signing ceremony ratified the agreement between Hirotsu Bio Science and the GHEF to expand the overseas deployment of N-NOSE to low- and middle-income countries, as agreed upon in a meeting on May 11th.
GHEF General Partner Dr. Morris Laster and the WHO Foundation’s Chief Executive Officer Anil Soni and Chief Impact Investment Officer Geetha Tharmaratnam visited Japan as representatives of the GHEF. Masayoshi Hirose, General Manager of Healthcare Dept., Infrastructure & Healthcare Division of Sojitz Corporation, who are cooperating in the overseas expansion of N-NOSE, attended the ceremony.
■Summary of the memorandum of understanding:
Hirotsu Bio Science, with its innovative cost-effective, comprehensive, and high-precision cancer testing, aims to support the overseas expansion of N-NOSE to low- and middle-income countries and contribute to the resolution of global health issues.
Hirotsu Bio Science Inc. firstname.lastname@example.org
HIROTSU BIO SCIENCE Corporation is proud to announce the opening of a store on Tmall Global, the largest cross-border EC platform in China opera . . .2023.08.22
On Thursday, March 16, "DAVOS 2023 DEBRIEFING" was held by the Consulate of Switzerland in Osaka.Our CMO/CGO, Shunsuke Mizushima, was invited as . . .2023.03.20
HIROTSU BIO SCIENCE releases a cancer screening for “Pet Dogs”. “N-NOSE Dogs” Website now available. －Pre-order available, special discounts ar . . .2023.03.10